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Abstract
Background: Monocytes/Macrophages (M/M) play a pivotal role as a source of virus during the
whole course of HIV-1 infection. Enhanced oxidative stress is involved in the pathogenesis of HIV-
1 infection. HIV-1 regulatory proteins induce a reduction of the expression and the activity of
MnSOD, the mitochondrial isoform leading to a sustained generation of superoxide anions and
peroxynitrite that represent important mediators of HIV-1 replication in M/M. MnTBAP
(Mn(III)tetrakis(4-benzoic acid)porphrin chloride), a synthetic peroxynitrite decomposition
catalyst, reduced oxidative stress subsequent to peroxynitrite generation.
Results: Virus production was assessed by p24 ELISA, western blot, and electron microscopy
during treatment with MnTBAP. MnTBAP treatment showed a reduction of HIV-1 replication in
both acutely and chronically infected M/M: 99% and 90% inhibition of p24 released in supernatants
compared to controls, respectively. Maturation of p55 and p24 was strongly inhibited by MnTBAP
in both acutely and chronically infected M/M. EC50 and EC90 are 3.7 (± 0.05) µM and 19.5 (± 0.5)
µM, in acutely infected M/M; 6.3 (± 0.003) µM and 30 (± 0.6) µM, in chronically infected M/M. In
acutely infected peripheral blood limphocytes (PBL), EC50 and EC90 are 7.4 (± 0.06) µM and of 21.3
(± 0.6) µM, respectively. Treatment of acutely-infected M/M with MnTBAP inhibited the elevated
levels of malonildialdehyde (MDA) together with the nitrotyrosine staining observed during HIV-1
replication. MnTBAP strongly reduced HIV-1 particles in infected M/M, as shown by electron
microscopy. Moreover, in presence of MnTBAP, HIV-1 infectivity was reduced of about 1 log
compared to control.
Conclusion: Results support the role of superoxide anions in HIV-1 replication in M/M and
suggest that MnTBAP may counteract HIV-1 replication in combination with other antiretroviral
treatments.
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Background
It is well know that monocytes/macrophages (M/M) are
important targets of human immunodeficiency virus type
1 (HIV-1) in infected patients. Such cells are widely recog-
nized to play a pivotal role as a source of virus during the
whole course of HIV-1 infection, even in patients receiv-
ing antiretroviral therapy [1]. HIV-1 infection does not
lead to M/M depletion as occurs for HIV-1 infected CD4+
T-lymphocytes; instead, once infected by HIV-1, M/M pro-
duce large amounts of infectious viral particles for a long
period of time [2]. Productively infected M/M can fuse
with CD4+ T-lymphocytes and transfer the virus to these
cells within the context of antigen presentation [3]; in
addition, infected M/M are able to trigger apoptosis of T-
lymphocytes (either CD4+ or CD8+) [4-6] as well as astro-
cytes, [7-9]. Few HIV-infected M/M are sufficient to induce
the recruitment and activation of HIV-infected resting
CD4+ lymphocytes [10] and infect resting CD4+ T-lym-
phocytes [11]. Recently, it has been demonstrated that as
few as 500 HIV-exposed M/M cause complete depletion of
several millions of autologous CD4+ T-lymphocytes, sus-
tained HIV-viremia and spreading of HIV-1-DNA in
mouse lymphoid organs [12]. Therefore, M/M sustain per-
sistent and continuously productive HIV infection [13].
Moreover, evidence exists suggesting that enhanced oxida-
tive stress may be involved in the pathogenesis of HIV
infection and HIV-1-infected patients are under chronic
oxidative stress [14-16]. The activation of CD4+ T-lym-
phocytes and M/M, which occurs during HIV infection, is
most likely due to increased production of free radicals
such as superoxide anion, peroxynitrite (the by-product of
super oxide and nitric oxide, NO) and hydroxyl radical
which is generated by peroxynitrite decomposition [8,17].
In addition, elevated serum levels of hydroperoxides and
malondialdehyde (MDA), which are recognized as mark-
ers of lipid peroxidation subsequent to free radical over-
production, have also been found in asymptomatic HIV-
1-infected patients early in the course of the disease [18].
Under normal circumstances, in healthy individuals, the
free radicals burden is highly regulated by the endogenous
antioxidant systems (i.e. superoxide dismutase enzymes,
SOD) and glutathione peroxidase. Previous studies sug-
gest that oxidative stress plays a crucial role during HIV-1
pathogenesis, including viral replication, inflammatory
response, decreased immune cell proliferation, loss of
immune function, chronic weight loss and increased sen-
sitivity to drug toxicity. In particular, the disruption of oxi-
dative status contributes to the cell damage observed
during HIV-1 infection, yet it is worth stressing that such
alteration is particularly relevant in M/M [18,19]. The
alteration of the homeostasis induced by HIV-1 infection
in M/M, with consequent production of toxic factors, is
claimed to be the main cause of neuronal damage during
AIDS [17]. In particular, the release of some coating com-
ponent of HIV-1, such as gp120 glycoprotein by HIV-1-
infected M/M produces both direct and indirect effects in
the central nervous system (CNS) and in the systemic
compartment [20,21]. The neuronal injury can result
from a direct mechanism by interaction with viral pro-
teins, such as gp120, Tat (Transcriptional transactivator)
and Vpr (viral protein R) produced by infected cells, or by
an indirect effect resulting from the inflammatory process
involving activated, though not necessarily HIV-1-
infected, monocytes, macrophages and astrocytes [22].
Furthermore, HIV-1 infection induces a significant pertur-
bation of oxidative status of M/M associated with an
increased production of MDA and a decreased synthesis of
endogenous glutathione [18]. In addition, the HIV regula-
tory proteins induce a reduction of expression and activity
of MnSOD, the mitochondrial isoform of the enzyme
[23], leading to a sustained generation of superoxide and
peroxynitrite and in turn imbalance of the cellular home-
ostasis [24,25].
The associations of HIV infection with the formation of
free radical species led us to hypothesize that superoxide
and peroxynitrite may represent important mediators of
M/M-HIV replication. To test this, we employed MnTBAP
(Mn(III)tetrakis(4-benzoic acid)porphrin chloride), a
synthetic peroxynitrite decomposition catalyst proven to
reduce oxidative stress subsequent to peroxynitrite gener-
ation [9,26].
Results
Acutely-infected macrophages
A significant dose dependent antiviral activity of MnTBAP
was achieved in acutely-infected M/M (i.e. treated with
drugs prior to virus challenge). In particular, the 1.2 µM
dose of MnTBAP led to a reduction of p24 gag Ag produc-
tion down to about 15% (Fig. 1). Indeed, concentration of
30 µM completely inhibited HIV-1 replication up to day
14, end of experiment, affording undetectable levels of
p24 gag Ag production (Fig. 1), no signs of toxicity were
observed at 30 µM (data not shown). Interestingly, virus
inhibition remained constant for all concentrations tested
up to day 14 (data not shown). Therefore, neither major
breakthrough nor cumulative inhibition of virus replica-
tion occurred in acutely-infected M/M at least up to 14
days after infection. EC50 and EC90 were then calculated
and found to be 3.7 (± 0.05) µM and 19.5 (± 0.5) µM,
respectively (Table 1).
Chronically-infected macrophages
To study the activity of MnTBAP in chronically-infected
M/M, antiviral treatment was started 10 days after infec-
tion, when both HIV-1 p24 gag Ag (Fig. 2) and genomic
HIV-RNA (data not shown) released in the supernatants
show a stable virus production. A decrease in the release
of mature proteins, compared to control, was already
detectable by day 5 after drug treatment with the highestRetrovirology 2007, 4:76 http://www.retrovirology.com/content/4/1/76
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concentrations of MnTBAP (30 µM and 6 µM) (Fig. 2),
and become more pronounced at day 10 (30 µM). This
event was similar to the inhibition observed when ampre-
navir (4 µM), a protease inhibitor employed as control of
chronic inhibition, was employed. Starting from day 5 of
drug treatment, and until the end of the experiment, a
quasi-stable and substantial inhibition of the release of
HIV-1 p24 gag Ag was detected with concentrations of
MnTBAP of 6 and 30 µM (about 50% and 90% at day 5,
respectively) up to day 10 after treatment. No complete
inhibition of virus replication could be achieved at the
highest non-toxic concentrations tested (Fig. 2). Based on
these data, EC50 and EC90 of MnTBAP were 6.3 (± 0.003)
µM and 30 (± 0.6) µM, respectively (Table 1). Treatment
with 10 µM of AZT (about 200-fold greater than its EC90
in HIV-1-acutely infected M/M) was not able to reduce the
production of HIV-1-p24 gag Ag in chronically infected
M/M (data not shown). This further confirms the absence
of new rounds of replication in these cells after day 10 of
infection [2,27].
Acutely-infected PBL
We wished to compare these results with those obtained
using protease inhibitors in PBL. MnTBAP has shown a
stable antiviral activity in acutely infected PBL until the
end of the experiment (day 10 after infection), with an
EC50 of 7.4 (± 0.06) µM and an EC90 of 21.3 (± 0.6) µM
(Table 1). These EC50 and EC90 are and in the range (or
lower in the case of EC90) of those determined in acutely
infected M/M (Table 1).
Drug toxicity
Treatment of M/M and PBL with concentrations of MnT-
BAP showed no decrease in cell number, thus suggesting
the absolute absence of major toxicity at used concentra-
tions (Table 1). Thus, the antiviral activity observed in
these experiments can be attributed only to the MnTBAP
inhibitory effect.
HIV-1 p24 and p55 gag proteins analysis
The western blots of lysates of acutely and chronically
infected M/M treated with MnTBAP are shown in Fig. 3.
When the M/M lysates were examined, the inhibition of
HIV-1-p24 antigen release into the supernatants corre-
lated with the disappearance of the p24 band in the
immunoblots in both acutely and chronically infected M/
M. Interestingly, HIV-1 p55 antigen was also inhibited by
MnTBAP treatment (Fig. 3) showing that MnTBAP is able
to counteract both the p24 as the precursor p55 forma-
tion, revealing the ability of MnTBAP to block the matura-
tion of p24 viral protein.
Selective inactivation of peroxynitrite in HIV-1 infected 
macrophges
Furthermore, HIV-1 replication was associated with an
increase of MDA level and nitrotyrosine staining indicat-
ing the HIV-related peroxynitrite formation (Fig. 4, 5A) as
evaluated 14 days after HIV-infection. Treatment of
acutely-infected M/M with MnTBAP (0,24–30 µM) inhib-
ited the MDA formation in a dose response manner (Fig.
Antiviral activity of MnTBAP in acutely HIV-1 infected mac- rophages Figure 1
Antiviral activity of MnTBAP in acutely HIV-1 
infected macrophages. Monocytes were cultured for 5 
days to generate monocyte-derived macrophages which 
where infected with 300 TCID50/ml HIV-1 BaL and treated 
acutely (i.e. treated with drugs prior to virus challenge). 
Supernatants were collected day 14 after infection and tested 
for virus production by analysis of HIV-1 p24 gag Ag produc-
tion with a commercially available kit ELISA.
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Table 1: Comparative anti-HIV-1 efficacy of MnTBAP in macrophages and lymphocytes
Cells EC50 (mM) EC90 (mM) TC50 (mM)
Macrophages
Acutely infected 3.7 (± 0.05) 19.5 (± 0.5) 60
Cronically infected 6.3 (± 0.003) 30 (± 0.6) 60
Limphocytes
Acutely infected 7.4 (± 0.06) 21.3 (± 0.6) 50
The geometric mean of p24 gag Ag production of replicates in each experiment was used to determine the effective drug concentration where 50% 
and 90% of viral replication is inhibited (EC50 and EC90, respectively), by linear regression of the log of the percent HIV-1-p24 production 
(compared to untreated controls) versus the log of the drug concentration. TC50: toxic concentration 50%; drug toxicity has been assessed in the 
absence of viral infection.Retrovirology 2007, 4:76 http://www.retrovirology.com/content/4/1/76
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4) and nitrotyrosine staining observed during HIV-1 rep-
lication (30 µM; Fig. 5D) by removing the superoxide and
peroxynitrite formation. As a control and consistent with
previously published data, 0.05 µM AZT induced about
90% inhibition of virus replication in these acutely
infected M/M (Fig. 1), but did not affected the nitrotyro-
sine staining nor MDA level (Fig. 4, 5C).
Effects of MnTBAP upon virus infectivity
We investigated the production of infectious virus parti-
cles by both acutely and chronically infected M/M. Super-
natants of HIV-1 acutely and chronically infected M/M
previously treated with MnTBAP 6 µM and 30 µM, respec-
tively, were titered in cultures of M/M and compared with
the infectivity of not treated HIV-1 infected M/M superna-
tants taken at the same time-point. The infectivity of
supernatants of not treated HIV-1 acutely infected M/M
had a titer of 6.57 × 103 TCID50/ml (Fig. 6A), while super-
natants from MnTBAP (6 µM) treated HIV-infected M/M
showed a not detectable infectivity (Fig. 6A). Similarly,
the infectivity of supernatants of not treated HIV-1 chron-
ically infected M/M had a titer of 5.62 × 103 TCID50/ml
(Fig. 6B), while supernatants from MnTBAP (30 µM)
treated HIV-infected M/M had a titer of 4.21 × 102 TCID50/
ml (Fig. 6B), that means a reduction of more than 92% of
infectivity.
Ultrastructural analysis of acutelly-infected M/M treated 
with MnTBAP
In order to better understand the mechanism through
which the removal of peroxynitrite was acting on HIV-1
acutely infected M/M, electron microscopy was performed
at day 14 after treatment. It is know that the mature HIV-
1 particles are accumulated in intracytoplasmic vacuoles
in M/M before the budding. As shown in Figure 7, MnT-
BAP at concentration of 6 µM dramatically reduced the
presence of HIV-1 particles inside cytoplasmic vacuoles
and in the extracellular compartment (Fig. 7). Moreover,
the number of these cytoplasmic vacuoles was dimished
by MnTBAP treatment in HIV-1-infected M/M, compared
to untreated HIV-1-infected M/M. These observations
MnTBAP inhibits MDA in HIV-infected macrophages in a  dose dependent fashion Figure 4
MnTBAP inhibits MDA in HIV-infected macrophages 
in a dose dependent fashion. MDA increased within HIV-
1-infected macrophages. Treatment with MnTBAP (0,24–30 
µM) antagonized MDA overproduction dose-dependently 
while AZT (0.05 µM) was not able to inhibit macrophages 
HIV-related MDA formation. † P < 0.001 when compared to 
control; * P < 0.05 and ** P < 0.001 when compared to HIV-
infected cells.
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Antiviral activity of MnTBAP in chronically HIV-1 infected  macrophages Figure 2
Antiviral activity of MnTBAP in chronically HIV-1 
infected macrophages. Monocytes were cultured for 5 
days to generate monocyte-derived macrophages which 
where infected with 300 TCID50/ml HIV-1 BaL and treated 
chronically (i.e. treated with drugs 10 days after infection) 
with MnTBAP at indicated doses, and Amprenavir (4 uM). 
Supernatants were collected at day 8, 10, 15, 20 after infec-
tion and tested for virus production by analysis of HIV-1 p24 
gag Ag production with a commercially available kit ELISA.
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MnTBAP reduces p24 and p55 expression in HIV-infected  macrophages Figure 3
MnTBAP reduces p24 and p55 expression in HIV-
infected macrophages. Western blots of lysates of acutely 
and chronically infected M/M. Line 1: Mock-infected macro-
phages. Line 2: macrophages HIV-1 BaL infected and treated 
with MnTBAP (30 µM). Line 3: macrophages HIV-1 BaL 
infected.
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might contribute to the profound infectivity reduction
induced by MnTBAP treatment that is able to disturb the
HIV-1 protein maturation.
Discussion
The design of this study was based on the crucial impor-
tance of infected macrophages in the pathogenesis and
progression of HIV-1 infection. During HIV-1 infection
the imbalance of the intracellular redox status due to
inflammatory stress has been previously reported [28].
Indeed, free radicals are generated following HIV infec-
tion of macrophages and microglia [1,12,17]. In particu-
lar, HIV-1 replication is enhanced under oxidative
condition in vitro [29]. For example, in vitro HIV-1 infec-
tion of macrophages resulted in superoxide and peroxyni-
trite production [30,31]. Indeed, our findings have shown
that immunohistochemical staining for nitrotyrosine, the
footprint of peroxynitrite, showed extensive immunoreac-
tivity in HIV-1 macrophages cytoplasm and this overpro-
duction was counteracted by MnTBAP, but not by AZT
treatment. In addition, HIV-infected macrophages pre-
sented elevated levels of malonildialdehyde, the bio-
chemical marker of lipid peroxidation that were inhibited
by MnTBAP treatment in a dose-dependent fashion.
Furthermore, significant and sustained inhibition of HIV-
1 replication was obtained in both acutely and chronically
infected macrophages by removing the overt production
of peroxynitrite. The effect of MnTBAP, a peroxynitrite
decomposition catalyst, upon both the core protein p24
and its precursor p55 suggests that that free radicals may
interfere with HIV-1 protein expression in both acute and
chronic infection thus suggesting the important role
played by the oxidative status in HIV-1 replication. This is
in agreement with previous observations which point out
the role of oxidative stress in HIV-1 proteins maturation
and folding in both lymphocytes and macrophages [32-
34]. Moreover, western blot analysis revealed that MnT-
BAP, by inhibiting both the p24 as the p55 formation, is
able to counteract not only the formation, but also the
maturation of this core viral protein. To confirm that
MnTBAP is able to act on the virus maturation the forma-
tion of mature viral particles in intracytoplasmic vacuoles
of M/M has been analyzed by electron microscopy. It is
MnTBAP inhibits nitrotyrosine formation in HIV-infected macrophages Figure 5
MnTBAP inhibits nitrotyrosine formation in HIV-infected macrophages. Photomicrographs (optical microscopy) of 
nitrotyrosine staining in HIV-1-infected macrophages. HIV-1 infection enhance the immunocytochemical expression of nitroty-
rosine (Panel A) in compared to mock-infected macrophages (Panel B), indicating an increased production of peroxynitrite. 
Acute treatment with MnTBAP (30 µM) (Panel D), but not with AZT (0.05 µM) (Panel C) is able to inhibit in macrophages 
HIV-related peroxynitrite formation.
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known that the mature HIV-1 particles are accumulated in
intracytoplasmic vacuoles in M/M before the budding.
Indeed, electron microscopic analysis of intracellular
compartments in HIV-1 infected M/M has shown that the
number of mature virus particles was dramatically
decreased by MnTBAP. Moreover, virus particles budding
was also fully inhibited in agreement with previous stud-
ies where restoration of the oxidative status homeostasis
led to the inhibition of HIV-1 budding in macrophage
cells. These results so can indicate that MnTBAP disturbs
the HIV-1 proteins maturation.
Lack of HIV-1 maturation is correlated to a dramatic
reduction of virus infectivity. The production of infectious
virus particles by both acutely and chronically infected M/
M was strongly counteracted (a reduction of about 4 and
2 log, respectively) by MnTBAP treatment. Nevertheless,
complete inhibition of HIV replication was not achieved.
This is not surprising since all the HIV inhibitors are less
(or even not) active in chronically-infected when com-
pared with acutely-infected macrophages [27,35,36].
It can be hypothetized that the dramatic virus inhibition
obtained by the employment of peroxynitrite decomposi-
tion catalyst is due to, at least in part, an indirect mecha-
nism on NF-kB pathway. Indeed, it is well known that
reactive oxygen species activate NF-kB that, in turn, is an
obligatory step for HIV-1, together with several viruses,
replication [[37,38], although further experiments are
needed to confirm this hypothesis].
Conclusion
However, other than this hypothesis, overall data pre-
sented in this article suggest that the inhibition of virus
maturation and release can be related to a block of post-
transcriptional/post-translational events of the virus life
cycle. In fact, MnTBAP treatment substantially modify the
expression of virus proteins in chronically (better in
acutely) infected macrophages. This structural proteins
are crucial for the infectivity of HIV-1. Nevertheless, we
cannot exclude that other factors related to peroxynitrite
inactivation influence the virus replication. In conclusion
our results highlight the role of peroxynitrite generation
in HIV replication in human macrophages and show that
the removal of peroxynitrite by selective antioxidants such
as peroxynitrite decomposition catalysts contribuits to the
inhibition of HIV replication in macrophages, the cells
acting as a reservoir of the virus. Furthermore, data here
reported suggest the potential usefulness of these com-
pounds alone or in association with other antiretrovirals
and may represent the basis for alternative and efficient
strategies for the treatment of HIV-1 infection.
Methods
Compounds
The peroxynitrite decomposition catalyst MnTBAP was
purchased from Alexisis Biochemicals (Switzerland). 3'-
azido-2', 3'-dideoxythymidine (AZT), an inhibitor of HIV
replication, was used as control at concentrations known
to be active against HIV-1 replication. All compounds and
reagents (with the exception of MnTBAP) were obtained
from Sigma (St. Louis, USA). The nucleoside analogue
reverse transcriptase inhibitor AZT was diluted in PBS and
stored at -80°C before using.
Cell cultures
Macrophages and lymphocytes
Primary M/M were prepared and purified as previously
described [39]. Briefly, PBMC obtained from healthy HIV-
Removal of free radicals by MnTBAP is involved in macro- phages HIV replication Figure 6
Removal of free radicals by MnTBAP is involved in 
macrophages HIV replication. Infectivity of virus parti-
cles produced by HIV-1-infected macrophages was evaluated 
on macrophages obtained from a different seronegative 
donor exposed to serial dilution of supernatants from MnT-
BAP treated or not-treated HIV-1-infected macrophages. 
The TCID50/ml was calculated according to Reed and 
Muench method. MnTBAP reduces TCID50 about a log both 
in acutelly (Panel A) as in chronically (Panel B) HIV-1-infected 
macrophages compared to infected and non treated macro-
phages.
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1-negative donors were separated over Ficoll gradient and
seeded in 48-well plates or in glass chamber (for immuno-
cytochemical analysis) at 1.8 × 106 cells/well in 1 ml of
RPMI 1640 containing 20% heat-inactivated, endotoxin
and mycoplasma-free fetal bovine serum (Hyclone Labo-
ratories, Inc., Logan, UT), 4 mM L-glutamine (Life Tech-
nologies), 50 U/ml penicillin and 50 µg/ml streptomycin
(Life Technologies) (herein after referred to as complete
medium). Five days after plating and culturing the PBMC
at 37°C in a humidified atmosphere enriched with 5%
CO2, non-adherent cells were carefully removed by
repeated washings with warmed RPMI 1640, leaving a
monolayer of adherent cells which were finally incubated
in complete medium. Cells treated under these conditions
have been shown to be >97% M/M, as determined by
cytofluorimetric analysis [39,40].
Peripheral blood lymphocytes (PBL) were purified from
PBMC by repeated adherences to remove monocytes, and
then cultured with the same medium as M/M, supple-
mented with 2 µg/ml phytohemagglutinin (PHA). Stimu-
lation was carried out for 72 hours; afterward, the
medium was discarded, cells were washed three times
with RPMI 1640 and the concentration was adjusted to 5
× 105 cells per ml of medium supplemented with 50 U/ml
recombinant interleukin-2 (IL-2).
HIV-1 isolates
Two different viral isolates of HIV-1 were used in this
study. A monocytotropic isolate of HIV-1 such as HIV-1BaL
was used in all experiments involving primary M/M. Char-
acteristics and genomic sequence of this strain have been
previously described [41-44]. The virus was expanded in
M/M, whose supernatants were collected, filtered and
Electron microscopy of untreated or MnTBAP-treated HIV-1 infected macrophages Figure 7
Electron microscopy of untreated or MnTBAP-treated HIV-1 infected macrophages. Untreated macrophages 
show accumulation of many mature particles, at different stages of maturation, in cytoplasmatic vacuoles and in the extracellu-
lar space. By contrast in MnTBAP (30 µM) treated macrophages no viral particles are found. This observation support the 
hypothesis that MnTBAP treatment is able to prevent enveloped and unenveloped virions production.
HIV HIV HIV
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stored at -80°C before use [44]. Characteristics of viral
stocks used for this study were 2.1 × 108  HIV-RNA
genomes/ml (corresponding to 35 ng of p24 antigen) and
5 × 103  tissue culture infectious doses 50% per ml
(TCID50/ml) as assessed by virus titration in other primary
M/M cultures. The prototypic lymphocytotropic strain of
HIV-1, named HIV-1IIIB  and used to infect PBL, was
obtained from acutely infected H9 CD4+ T-lymphocytes
cell line, and then expanded in PBMC. Cell free virus
present in the supernatants was collected, ultracentri-
fuged, filtered (0,22 µM) and stored at -80°C. Titre of
HIV-1IIIB  viral stocks used in this study was 5 × 106
TCID50/ml, as assessed in CD4+ T-lymphocytic cell line
C8166.
Drug toxicity
M/M and PBL were treated for 14 to 21 days in the pres-
ence of different concentrations of MnTBAP. Cell viability
of M/M and PBL was visually assessed (and compared to
untreated controls) using the trypan blue exclusion
method. Briefly, cells were exposed to dye, and then visu-
ally examined to determine whether cells take up or
exclude dye. The live cells that possess intact cell mem-
branes exclude trypan blue, whereas dead cells do not.
Drug toxicity was assessed in the absence of viral infec-
tion.
Assessment of drug activity in acutely infected M/M
One day after separation (i.e. 6 days after plating), M/M
were treated with various concentrations of drugs (MnT-
BAP, 0.24, 1.2, 6 and 30 µM; AZT, 0.05 µM), and then
exposed to 300 TCID50/ml of HIV-1Ba-L  (a virus dose
affording a maximal virus production from M/M). Two
hours after virus challenge, M/M were washed to remove
the viral inoculum, and complete medium containing the
appropriate drugs was replaced. Macrophages were then
cultured for the duration of the experiments by refunding
them with fresh complete medium and drugs every 2 days.
Supernatants were collected at different time points for
assessment of virus production by analysis of HIV-1 p24
gag Ag production with a commercially available kit
(Abbott labs, Pomezia, Italy) as described before. The p24
gag Ag evaluation was repeated at later time points in
selected experiments; the geometric mean of p24 gag Ag
production of replicates in each experiment was used to
determine the effective drug concentration where 50%
and 90% of viral replication is inhibited (EC50 and EC90,
respectively), by linear regression of the log of the percent
HIV-1-p24 production (compared to untreated controls)
versus the log of the drug concentration.
Assessment of antiviral drug activity in chronically infected M/M
M/M were defined chronically infected when no new
rounds of infection occurr in in vitro cultures and the p24
production remains stable. Our previous experience dem-
onstrated that such status of chronical infection occurs
starting from day 10 after virus challenge. For this pur-
pose, M/M were challenged with 300 TCID50/ml of HIV-
1BaL (in the absence of any drug) at day 0, and p24 gag Ag
analysis was carried out from day 6 up to the point when
at least two consecutive determinations showed stable
production (around day 10–14 in all experiments per-
formed for this purpose). At the time of chronical infec-
tion (hereinafter called day 0 for these experiments with
chronically-infected M/M), M/M were carefully washed at
least twice to remove any virus present in the superna-
tants, replenished with fresh complete medium contain-
ing various concentrations of MnTBAP (0.24–30 µM),
Amprenavir (4 µM) or AZT (10 µM), and cultured under
the same conditions as described before. Each drug con-
centration was run in triplicate or quadruplicate while
positive controls were run in sextuplicate. Therefore,
unless differently stated, drugs were then added at the
time of chronical infection (i.e. day 10), and replaced each
time of medium change (i. e. every 2 days).
Assessment of drug activity in acutely-infected PBL
PBL were plated in 48-well plates in the presence or
absence of various concentrations of drugs, and chal-
lenged 30 minutes later with 300 TCID50/ml of HIV-1IIIB.
After 2 hours cells were washed, counted, and plated with
complete medium containing the appropriate drugs con-
centrations. Assessment of virus replication was per-
formed by HIV-1-p24 ELISA.
Virus infectivity
Infectivity of virus particles produced by HIV-1-infected
M/M was evaluated on M/M obtained from a different
seronegative donor exposed to serial dilution of superna-
tants from drug treated or not-treated HIV-1-infected M/
M. The TCID50/ml was calculated according to Reed and
Muench method.
Western blot analysis
After cells were washed with phosphate-buffered saline
(PBS, BioWhittaker, Walkersville, MD), they were lysed
with 0.75% Triton X-100 lysis buffer containing 300 mM
NaCl, 50 mM Tris-HCl, pH 7.4, 2 µL/mL DMSO, and a
cocktail of protease inhibitors containing 10 µg/mL Leu-
peptin, 20 µg/mL Aprotinin, 25 µM p-nitrophenyl guanid-
inobenzoate (pNGb). After a ten minute incubation in
lysis buffer at 4°C, the cell lysate was clarified by centrifu-
gation for ten minutes at 10,000 rpm. Total protein con-
centration was determined using the BCA Assay (Pierce,
Rockford, IL). Cell lysates were resuspended in SDS sam-
ple buffer containing 50 mM dithiotreitol (DTT). Cell
lysates (2 µg) were then loaded in a 10% Bis-Tris polyacr-
ylamide gel (Novex, San Diego, CA), after separation by
SDS/PAGE, proteins were transferred electrophoretically
to nitrocellulose membranes and detected with a mono-Retrovirology 2007, 4:76 http://www.retrovirology.com/content/4/1/76
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clonal mouse antibody to HIV-1-p24 (Intracel, Cam-
bridge, MA).
Immunocytochemical Staining
Immunocytochemical staining for nitrotyrosine was per-
formed on treated or not treated M/M. M/M were fixed
with 4% paraformaldeyde dissolved in 0.1% phosphate
buffer (pH 7.4). Nonspecific staining was blocked with
3% normal goat serum in 0.5 M Tris-HCl, pH 7.4 contain-
ing 0.2% Tween 20 for 1 h at room temperature. All sub-
sequent incubations were carried out in this buffer. For
detection of nitrotyrosine immunoreactivity, cells were
incubated overnight at 4°C with an anti-nitrotyrosine
monoclonal Ab (Cayman, 1:500). Treatment with sec-
ondary antibody, A/B complex, and DAB were performed
by the manufacturer's instructions (Vector ABC Elite Kit,
Vector Laboratories).
Malondialdehyde Determinations
Malondialdehyde (MDA), used as a biochemical marker
for lipid peroxidation, was measured by a method previ-
ously described [45]. Briefly, cells were homogenized in
potassium chloride (1.15%) and frozen in liquid nitro-
gen. Chloroform (2 ml) was then added to each homoge-
nate and then spun for 30 min. The organic layer of the
sample was removed and dried under nitrogen gas and
reconstituted with 100 µl of saline. MDA generation was
evaluated by the assay of thiobarbituric acid (TBA)-react-
ing compounds. The addition of a solution of 20 µl of
sodium dodecyl sulphate (SDS; 8.1%), 150 µl of 20% ace-
tic acid solution (pH3.5), 150 µl of 0.8% TBA and 400 µl
of distilled water, produced a chromogenic product which
was extracted in n-butanol and pyridine. Then, the
organic layer was removed and MDA levels read at 532
nm and expressed as nmol MDA/g prot.
Ultrastructural studies
Cells for electron microscopy were fixed in 2.5% glutaral-
dehyde in PBS pH7.4 at 4°C and then washed for 2 hours
in PBS and post fixed in osmium tetroxide 1.33% for 2
hours at 4°C. After several washes in PBS, the cells were
dehydrated in graded alcohol, transferred into toluene,
and embedded in Epon 812 resin. The resin was allowed
to polymerize in a dry oven at 60°C for 24 hours. Thin
sections were cut with a glass knife Reichert microtome,
stained with toluidine blue and examined on Axioscope
microscope. Ultra-thin sections were cut on a Reichert
microtome using a diamond knife, stained with uranyl-
acetate-lead-hydroxide and evaluated and photographed
on a Philips electron microscope CM 10 (Philips).
Statistics
The differences in the EC50 in different cell populations
and under different conditions of infection were assessed
using the Student's t test. Results are given as mean ± sem.
Statistical analysis was performed using ANOVA followed
by Student-Newman-Keuls. P < 0.05 was considered sta-
tistically significant.
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